In Caucasian patients with metastatic colorectal cancer (CRC) treated with FOLFIRI (irinotecan, bolus and continuous-infusion fluorouracil, leucovorin), the T allele at NR1I2 rs1054190 (C > T) was associated with worse overall survival (OS) and progression-free survival (PFS), identifying NR1I2-rs1054190 polymorphism as a potential prognostic marker of OS [59]. Here, NR1I2 is linked to metastatic colorectal cancer.